Andorra pharmacists see no evidence of Ozempic/Mounjaro black market

Pharmacists in Andorra say they have no evidence of a black market for weight‑loss drugs operating in the principality. Jesús Robinat, president of the Col·legi de Farmacèutics d’Andorra, responded to an El País report that described a parallel market for Ozempic and other slimming medicines and detailed a network allegedly active in Gibraltar.

El País quoted a purported supplier of powdered Mounjaro—one of the drugs named alongside Ozempic and Wegovy—operating outside regulated pharmaceutical channels. Such clandestine distribution, the paper said, would pose public‑health risks because these medicines are prescription‑only and should be dispensed under medical supervision.

Robinat said the activities described had not been detected by pharmacists locally. He added the individual in question “lived in Andorra for a while and did certain things that have nothing to do with the pharmaceutical sector,” and that those clandestine operations have ceased. “As far as we know, there is nothing,” he reiterated, noting that some buyers had used Telegram to request products and were largely motivated by price.

On the official supply side, Robinat said pharmacy operations and stocks of Ozempic, Mounjaro and Wegovy have “normalised.” He acknowledged there had been a period when Ozempic was out of stock for a considerable time.

Robinat also clarified differences in prescription and coverage: Ozempic is the only one of the three reimbursed by the CASS and is prescribed for lowering blood glucose in diabetes. Wegovy and Mounjaro are indicated primarily for weight loss. “One thing is the indication and another is the active ingredient,” he said, pointing out that Wegovy contains the same active ingredient as Ozempic but is approved in Spain only for weight loss and is not covered by social security, whereas Mounjaro has a different active ingredient.